Screen readers: Two navigational links to follow.Skip to site navigation.Skip to page content.
The University of Iowa News Services
The University of Iowa News Services Home News Releases UI in the News Subscribe to UI News Contact Us

University of Iowa News Release


Oct. 6, 2008

UI flu study seeks adults age 65 and older

Adults age 65 and older who are in overall good health are invited to participate in a University of Iowa research study on influenza vaccines.

The study will evaluate the effectiveness and safety of a study flu vaccine called Afluria compared to a flu vaccine called Fluzone. Afluria is a licensed influenza vaccine for people younger than age 65. The goal of this study is to assess the immune response and safety of the flu vaccine Afluria in healthy older adults.

Individuals who are allergic to eggs or who have had severe reactions to a vaccine are not eligible to participate.

Participation involves two visits over three weeks to UI Hospitals and Clinics, followed by a telephone interview six months later. Participants will be randomly assigned to receive either Afluria or Fluzone. Participants must be willing to provide blood samples. Costs will be covered for all study drugs, tests and exams. Compensation is available.

The study is funded by CSL Limited, which manufactures Afluria. Approximately 1,300 participants will be enrolled at nine sites nationwide, including an expected 130 individuals at the UI. Patricia Winokur, M.D., UI associate professor of internal medicine, is the principal investigator for the UI site.

For more information, call 319-384-7245 between 8 a.m. and 5 p.m. Monday through Friday or email

STORY SOURCE: University of Iowa Health Science Relations, 5137 Westlawn, Iowa City, Iowa 52242-1178

MEDIA CONTACT: [The following contact information is for reporters only; please use the contact information provided in the last paragraph of the news release to reach the study coordinator.] Becky Soglin, 319-335-6660, Health Science Relations,